Inadequate Response to PCSK9 Inhibitors
A higher rate of suboptimal PCSK9i responses have been reported in real-world data than in randomized clinical trials (7.5% vs 1%), warranting further investigation to understand mechanisms. The use of combination therapy based on individual response and tolerance is essential to assure goal attainment and improve residual risk in patients with suboptimal response.
Authors
- Courtney Davila
- Michael D. Shapiro (ORCID: https://orcid.org/0000-0002-9071-3287)
- Eugenia Gianos (ORCID: https://orcid.org/0000-0001-7720-7470)
- Sean M. Donahoe
- Maya Safarova (ORCID: https://orcid.org/0000-0003-3069-3752)
- Tanesh Ayyalu (ORCID: https://orcid.org/0000-0002-8804-4096)
- Tia Bimal
- Thomas Dayspring (ORCID: https://orcid.org/0000-0002-5874-7305)
Institutions
- Medical College of Wisconsin (US)
- Lenox Hill Hospital (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- Institute for Global Engagement (US)
- Peconic Bay Medical Center (US)
- Wake Forest University (US)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.jaccas.2025.103696
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 4.01